Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) was the recipient of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 2,645,906 shares, a drop of 32.0% from the August 31st total of 3,889,264 shares. Based on an average daily trading volume, of 920,846 shares, the short-interest ratio is presently 2.9 days. Currently, 5.2% of the company’s shares are sold short.

Several analysts have commented on the stock. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research report on Saturday, September 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. Stifel Nicolaus reissued a “buy” rating and issued a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Piper Jaffray Companies started coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They issued an “overweight” rating and a $14.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $11.13.

In other news, insider Jacques Dumas sold 17,500 shares of the business’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total value of $105,000.00. Following the completion of the transaction, the insider now owns 17,500 shares of the company’s stock, valued at approximately $105,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 5.50% of the company’s stock.

Institutional investors have recently modified their holdings of the business. AXA acquired a new position in shares of Tetraphase Pharmaceuticals in the second quarter valued at about $132,000. Citadel Advisors LLC raised its stake in shares of Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after purchasing an additional 2,496 shares during the last quarter. Virtu KCG Holdings LLC purchased a new position in shares of Tetraphase Pharmaceuticals in the second quarter worth about $147,000. Voya Investment Management LLC raised its stake in shares of Tetraphase Pharmaceuticals by 17.8% in the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 3,104 shares during the last quarter. Finally, UBS Group AG raised its stake in shares of Tetraphase Pharmaceuticals by 2.3% in the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 387 shares during the last quarter. Institutional investors and hedge funds own 41.73% of the company’s stock.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 7.25 on Wednesday. The firm has a 50-day moving average price of $6.63 and a 200-day moving average price of $7.29. The firm’s market capitalization is $370.13 million. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The firm had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $1.54 million. During the same period in the previous year, the company earned ($0.47) EPS. The company’s revenue was up 28.2% on a year-over-year basis. Analysts expect that Tetraphase Pharmaceuticals will post ($2.54) EPS for the current year.

WARNING: “Tetraphase Pharmaceuticals, Inc. (TTPH) Short Interest Update” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/tetraphase-pharmaceuticals-inc-ttph-short-interest-update/1606368.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.